P-63: The Effect of Bromocriptine Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: A Randomized Prospective Clinical Trial

Background: To assess whether Bromocriptine Rebound Method (BRM), can improve pregnancy outcomes after intracytoplasmic sperm injection (ICSI) cycles. Materials and Methods: In this prospective study, we analyzed data from a total of 117 women who underwent ICSI cycles. Pregnancy outcomes and hormonal data were compared between long protocol and BRM groups. Ovulatory women with normal serum prolactin levels were assigned to either the BRM(n=59 cycles) or long protocol (n=58 cycles). Both procedures were performed in a similar ways, the only deference was that Bromocriptine was administered daily from day 4 the preceding cycle until the 7 days before gonadotropin stimulation in BRM group. Results: No significant differences were observed in the numbers of developed follicles, total retrieval oocytes, embryos transfered and embryos with superior morphology. The values of chemical, clinical and ongoing pregnancies and live births were not significantly differences between two groups (37%, 35%, 28.1%, 28.1% in group I and 44%, 38.6%, 21.1%, 19.3% in group II respectively); ongoing pregnancies and live births were sinificantly higher in chemical pregnant BRM group. Conclusion: The results of this prospective study revealed that BRM might lead to higher ongoing pregnancy and live birth rates compared to long protocol in women undergoing ICSI cycles.